Study validates shorter treatment for major world infection, tuberculosis
Four-month TB therapy proves as effective as 6-month standard regimen
SAN ANTONIO (May 19, 2021) -- Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time by a third. Coauthors including Marc Weiner, MD, of The University of Texas Health Science Center at San Antonio, reported the findings May 6 in the New England Journal of Medicine.
"Shorter treatment would be easier for people to complete without missing doses, and ultimately may be cost-effective," said Dr. Weiner, associate professor in the health science center's Joe R. and Teresa Lozano END
"Shorter treatment would be easier for people to complete without missing doses, and ultimately may be cost-effective," said Dr. Weiner, associate professor in the health science center's Joe R. and Teresa Lozano END